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Continuous glucose monitoring system: 
dawn period calibration does not 
change accuracy of the method
Sistema de monitorização contínua de glicose: calibração 
da madrugada não interfere na acurácia do método
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Maria L. C. Correa-Giannella1, Marcia Nery1, Karla F. S. de Melo1
ABSTRACT
Introduction: Continuous glucose monitoring system is a valuable instrument to measure 
glycemic control, which uses a retrospective calibration based upon 3 to 4 capillary glucose 
meter values inserted by the patient each day. Objective: We evaluated the interference of ca-
libration during the dawn period in the system accuracy. Methods: The monitoring data were 
retrospectively divided into two groups: with (Group A) or without (Group B) the dawn period 
calibration (between 1:00 and 5:00 AM). Accuracy of the method was expressed by relative 
absolute difference. Results: Thirty-four continuous glucose monitoring data were evaluated 
comprising a total of 112 nights. A total of 289 paired readings were analyzed – 195 in Group A 
and 94 in Group B. We did not find a difference in relative absolute difference (RAD%) in any 
analyzed period of day by adding dawn calibration. Conclusions: These data suggest that dawn 
calibration does not alter accuracy of method. Arq Bras Endocrinol Metab. 2009;53(4):425-8.
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RESUMO
Introdução: O CGMS (sigla do inglês continuous glucose monitoring system) é um instrumento 
valioso no controle glicêmico e utiliza uma calibração por meio de 3 ou 4 medidas de glicemia 
capilar inseridas pelo paciente em cada dia do exame. Objetivo: Avaliar a interferência da cali-
bração durante a madrugada na acurácia do sistema. Métodos: Os dados das monitorizações 
foram divididos retrospectivamente em dois grupos: com (Grupo A) ou sem (Grupo B) a cali-
bração da madrugada (entre 1:00 e 5:00 AM). A acurácia do método foi mostrada pela diferença 
relativa absoluta (DRA%). Resultados: Trinta e quarto dados de monitorização foram avaliados 
em um total de 112 noites. Um total de 289 leituras pareadas foi analisado – 195 no Grupo A e 
94 no Grupo B. Não foi encontrada diferença em DRA% em nenhum período do dia quando adi-
cionada a calibração durante a madrugada. Conclusões: Esses dados sugerem que a calibração 
da madrugada não altera a acurácia do método. Arq Bras Endocrinol Metab. 2009;53(4):425-8.
Descritores
Diabetes melito; controle glicêmico; hipoglicemia; monitorização contínua
InTRODUCTIOn
In the last years, the continuous glucose monitoring system (CGMS, Medtronic MiniMed, Northridge, 
CA) has arisen as a useful tool in glycemic evaluation 
of patients with diabetes, providing clinically relevant 
information for individuals with diabetes and their care 
providers (1,2). The CGMS uses a retrospective calibra-
tion based upon 3 to 4 capillary glucose meter values 
(CG) inserted by the patient each day, but there is no 
clear recommendation about the best time to perform 
CGMS sensor calibration (3,4).
Continuous glucose monitoring offers an opportunity 
to obtain detailed glucose control evaluation, especially 
during the overnight period, when the measurement of 
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CG by patients with diabetes is more difficult to obtain. 
The clinical practice has demonstrated that the number 
of blood glucose measurements during night-time is less 
frequent than desired to evaluate the adequacy of bedtime 
insulin dose, even when it is required by the care providers. 
Two recent studies (3,5) have suggested a reduction in the 
accuracy of the CGMS during night-time readings, with a 
tendency of lower values of interstitial glucose (IG) than 
CG. Moreover, DirectNet Study Group suggested that 
the sensor accuracy was much improved by calibrations 
when there was not a rapid rate of glucose change (3), for 
example, during the long fasting nocturnal period.
The present study was undertaken to evaluate the 
interference of CGMS calibration during the dawn pe-
riod in the system accuracy.
METhODS
All patients were followed up at the Hospital das Clíni-
cas (HC), in São Paulo. The study protocol was ap-
proved by the ethics committee of the hospital, and 
informed consent was obtained from the patients or 
their guardians. From 2003 to 2006, CGMS data of 
30 patients with type 1 and 2 diabetes, using intensive 
insulin therapy and presenting high levels of HbA1c 
and/or high frequency of hypoglycemia were retro-
spectively analyzed. CGMS sensors were inserted into 
the subcutaneous abdominal fat tissue. While wearing 
the CGMS, the patients were asked to perform, at least, 
four daily self monitoring of blood glucose (SMBG) 
tests by home glucose meter (Accu-Chek®; Roche®) 
and to enter these values into the CGMS for sensor 
calibration. Accuracy of the method was expressed by 
relative absolute difference (RAD%), calculated for each 
IG-CG pair: RAD% = CG-IG/CG (6).
Patients always performed SMBG calibration mea-
sures at night and, while fasting, during the exam days. 
The monitoring data were retrospectively divided into 
two groups: with (Group A) or without (Group B) the 
dawn period calibration (between 1:00 and 5:00 AM). 
A total of 289 paired readings were analyzed, 195 in 
Group A and 94 in Group B. Differences in the ac-
curacy in the morning period in relation to the night 
period between Groups A and B were studied. Clinical 
data of patients are showed in table 1.
The Pearson correlation coefficient (r) between CG 
and IG of Groups A and B was determined by linear 
regression. T-Student test was performed to compare 
the RAD% of Groups A and B. 
Table 1. Characteristics of patients
Group A B p-value
n 14 16
Male (%) 25% 21,4%
Age 26,4  ±  9,1 31,6 ± 15,9 0,32
Diagnosis (years) 14,7 ± 9,2 13,5 ± 8,0 0,73
DM1 100% 85,7%
HbA1c (%) 7,12 ± 0,8 9,11 ± 0,8 < 0,0001
Complications 25,0% 35,7%
Microalbuminuria 8,3% 28,5%
Retinopathy 25,0% 28,5%
Nephropathy 0,0% 14,2%
Neuropathy 8,3% 7,1%
RESUlTS
The 30 diabetic patients who participated in the study 
had a median age of 24.5 years (range 14 to 63 years); 
median time since diagnosis of 14.5 years (range 3 to 31 
years) and median HbA1c of 8.2% (range 5.6 to 11.2%). 
Twenty-four patients were female. Thirty-four conti-
nuous glucose monitoring data were evaluated comprising 
a total of 112 nights. Thirty percent of patients (8⁄30) had 
hypoglycemia during the evaluated nights, with a median 
duration of 200 minutes (range 30 to 500 minutes). 
We identified an adequate correlation between CG 
and IG in both Groups A and B with Pearson coef-
ficient (r) of 0.91 (p < 0.0001) and 0.96 (p < 0.0001), 
respectively. There was no difference in median fast-
ing RAD% among Groups A and B (7.4 versus 7.8%; 
p = 0.73); neither difference was seen in night-fasting 
RAD% variation between the two groups (-0.34 ver-
sus +1.91%; p = 0.75) (Figure 1). The mean RAD% of 
Group A was 12 ± 9.4 and, of Group B, it was 11 ± 7.7, 
with no difference between them.
DISCUSSIOn
CGMS allows continuous evaluation of glucose levels 
due to strictly correlation between IG and CG (7). 
Therefore, it could help handling patients with diabe-
tes, mainly using multiple doses of insulin, in associa-
tion with HbA1c and SMBG (8,9). There is a recom-
mendation to perform at least 3 to 4 calibrations/day, 
during continuous glucose monitoring. Studies ob-
served that the accuracy of CGMS is higher when more 
calibrations values are performed (10). We did not find 
a difference in RAD% in any analyzed period of day by 
adding dawn calibration.
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One of the most important indications of CGMS is 
the evaluation of hypoglycemia, especially asymptomatic 
episodes in the dawn period (11). In the presented 
study, 1/3 of the patients presented hypoglycemia 
during sleep. However, it has been noted that 
accuracy during this period is decreased, as well as in 
hypoglycemic episodes (3,5). In addition, hypoglycemia 
can be overestimated during the dawn period, due to 
physiologic differences in glucose uptake, utilization, 
and elimination in blood, interstitial space, and cells or 
a change in bioactivity of sensor (10,12). Furthermore, 
rapid changes in plasma glucose may not be followed by 
IG variation of the same degree and speed (13). In our 
study, we did not find an increased accuracy between 
CG and IG in the morning measurements of Group A 
(with dawn calibration) when compared with Group B, 
using relative absolute difference (RAD%). We also did 
not observe statistical difference between CG and IG 
fasting values of both groups.  
In their study, Guerci and cols. (14) compared 
CGMS accuracy with CG and blood sample glu-
cose. Coefficients of correlation ranged from 0.87 to 
0.92, and the mean absolute error ranged from 12.8 
to 15.7%. Only 39% of the CGMS values satisfied the 
American Diabetes Association (ADA) precision crite-
ria to within ± 10%, and 19% of these values satisfied 
the future ADA precision criteria of accuracy to within 
5%. Although the accuracy of CGMS can be improved, 
we observed an adequate correlation between CG and 
IG in our study, therefore we could evaluate glucose 
control during night-time.
These data suggest that dawn calibration does not 
alter accuracy of CGMS and it implies a more comfort-
able exam without the recommendation to perform a 
dawn period calibration.
Disclosure: no potential conflict of interest relevant to this article 
was reported. 
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